A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS)

Introduction. Despite the availability of effective biologic therapies for psoriasis, there is no gold-standard treatment for nonpustular palmoplantar psoriasis (ppPsO). Methods. G-PLUS, a phase IIIb, double-blind, placebo-controlled, multicentre clinical trial, randomised adults with moderate-to-se...

Full description

Saved in:
Bibliographic Details
Published in:Dermatologic therapy 2023, Vol.2023 (1)
Main Authors: Passeron, Thierry, Carrascosa, Jose Manuel, Warren, Richard B., Pinter, Andreas, Romanelli, Marco, Gorecki, Patricia, Efficace, Michela, Fakharzadeh, Steve, Yang, Ya-Wen, Azzabi, Ahlem, Jazra, Maria, Lemos, Katya, Leung, Monica, Chen, Yanqing, Thaçi, Diamant
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction. Despite the availability of effective biologic therapies for psoriasis, there is no gold-standard treatment for nonpustular palmoplantar psoriasis (ppPsO). Methods. G-PLUS, a phase IIIb, double-blind, placebo-controlled, multicentre clinical trial, randomised adults with moderate-to-severe nonpustular ppPsO and limited plaque psoriasis (Psoriasis Area and Severity Index (PASI) ≥3 but
ISSN:1396-0296
1529-8019
DOI:10.1155/2023/9967747